Union Bancaire Privee UBP SA Purchases Shares of 3,000 DexCom, Inc. (NASDAQ:DXCM)

Union Bancaire Privee UBP SA acquired a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 3,000 shares of the medical device company's stock, valued at approximately $225,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Versant Capital Management Inc acquired a new position in shares of DexCom in the 4th quarter worth approximately $25,000. Riverview Trust Co lifted its stake in DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock worth $31,000 after purchasing an additional 232 shares in the last quarter. RPg Family Wealth Advisory LLC purchased a new position in shares of DexCom during the third quarter worth $57,000. Covestor Ltd grew its stake in shares of DexCom by 53.7% in the third quarter. Covestor Ltd now owns 959 shares of the medical device company's stock valued at $64,000 after buying an additional 335 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB raised its holdings in shares of DexCom by 46.7% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company's stock valued at $65,000 after buying an additional 265 shares during the period. Institutional investors and hedge funds own 97.75% of the company's stock.

DexCom Stock Performance

Shares of DXCM traded up $1.16 during mid-day trading on Thursday, hitting $87.59. 983,304 shares of the company's stock were exchanged, compared to its average volume of 3,588,007. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The business's 50 day moving average is $80.22 and its two-hundred day moving average is $76.59. The firm has a market capitalization of $34.21 billion, a P/E ratio of 52.43, a P/E/G ratio of 2.23 and a beta of 1.12.

Insiders Place Their Bets

In other DexCom news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares of the company's stock, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

DXCM has been the topic of several research reports. JPMorgan Chase & Co. increased their price target on shares of DexCom from $75.00 to $85.00 and gave the stock a "neutral" rating in a research report on Friday, October 25th. Oppenheimer decreased their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Friday, October 25th. Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and upped their price objective for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Raymond James decreased their target price on DexCom from $115.00 to $99.00 and set a "strong-buy" rating for the company in a report on Friday, October 25th. Finally, Canaccord Genuity Group upped their price target on DexCom from $89.00 to $99.00 and gave the stock a "buy" rating in a report on Monday, December 9th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $99.29.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.